Abstract
Indoleamine 2,3-dioxygenase (IDO) is a heme-containing oxidoreductase that catalyzes the initial and rate-limiting step in the breakdown of non-dietary tryptophan. The biology and immunomodulatory role for IDO is discussed in this review with a focus on its interaction with immune cells and its potential therapeutic target in the clinic. IDO has been revealed to be a central regulator of immune responses in a broad variety of physiological and pathological settings, mostly serving as a multifaceted negative feedback mechanism, to self-regulate immune responses. IDO is considered a therapeutic target in cancer and the use of IDO inhibitors as single agent or in combination with other treatment modalities are under active investigation.
Keywords: Cancer immunotherapy, combination therapy, indoleamine 2, 3-dioxygenase (IDO), IDO inhibitors, immune tolerance.
Current Cancer Drug Targets
Title:Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies
Volume: 16 Issue: 9
Author(s): Senthamil R. Selvan, John P. Dowling, William K. Kelly and Jianqing Lin
Affiliation:
Keywords: Cancer immunotherapy, combination therapy, indoleamine 2, 3-dioxygenase (IDO), IDO inhibitors, immune tolerance.
Abstract: Indoleamine 2,3-dioxygenase (IDO) is a heme-containing oxidoreductase that catalyzes the initial and rate-limiting step in the breakdown of non-dietary tryptophan. The biology and immunomodulatory role for IDO is discussed in this review with a focus on its interaction with immune cells and its potential therapeutic target in the clinic. IDO has been revealed to be a central regulator of immune responses in a broad variety of physiological and pathological settings, mostly serving as a multifaceted negative feedback mechanism, to self-regulate immune responses. IDO is considered a therapeutic target in cancer and the use of IDO inhibitors as single agent or in combination with other treatment modalities are under active investigation.
Export Options
About this article
Cite this article as:
Selvan R. Senthamil, Dowling P. John, Kelly K. William and Lin Jianqing, Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies, Current Cancer Drug Targets 2016; 16 (9) . https://dx.doi.org/10.2174/1568009615666151030102250
DOI https://dx.doi.org/10.2174/1568009615666151030102250 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Progress in the Development of Natural ent-Kaurane Diterpenoids with Anti-tumor Activity
Mini-Reviews in Medicinal Chemistry Nano-Chitosan Particles in Anticancer Drug Delivery: An Up-to-Date Review
Mini-Reviews in Medicinal Chemistry Current Biomarkers for Lung Cancer
Current Signal Transduction Therapy Microglial Activation with Reduction in Autophagy Limits White Matter Lesions and Improves Cognitive Defects During Cerebral Hypoperfusion
Current Neurovascular Research Apoptosis is a Critical Cellular Event in Cancer Chemoprevention and Chemotherapy by Selenium Compounds
Current Cancer Drug Targets Cancer Molecular Imaging: Radionuclide-Based Biomarkers of the Epidermal Growth Factor Receptor (EGFR)
Current Topics in Medicinal Chemistry The HOX Genes Network in Uro-Genital Cancers: Mechanisms and Potential Therapeutic Implications
Current Medicinal Chemistry Prognostic and Therapeutic Implications of MicroRNA in Malignant Pleural Mesothelioma
MicroRNA Curcumin and Curcumin-like Molecules: From Spice to Drugs
Current Medicinal Chemistry β-Cyclodextrin Complexes of Hydrolyzable Adamantanoyl-IUdR Prodrugs - Radioiodination and Biodistribution in Mice Bearing Implanted KBALB Tumours
Current Radiopharmaceuticals Cytoprotective Agents to Avoid Chemotherapy Induced Sideeffects on Normal Cells: A Review
Current Cancer Drug Targets Targeted Therapy for Advanced Urothelial Cancer of the Bladder: Where Do We Stand?
Anti-Cancer Agents in Medicinal Chemistry Yttrium-90 – Current Status, Expected Availability and Applications of a High Beta Energy Emitter
Current Radiopharmaceuticals The Roles of Histone Demethylase UTX and JMJD3 (KDM6B) in Cancers: Current Progress and Future Perspectives
Current Medicinal Chemistry Carbonic Anhydrase Inhibitors Developed Through ‘Click Tailing’
Current Pharmaceutical Design Looking out for Cancer Stem Cells’ Properties: The Value-Driving Role of CD44 for Personalized Medicines
Current Cancer Drug Targets Anticancer Peptides and Proteins: A Panoramic View
Protein & Peptide Letters β -Glucans and their Applications in Cancer Therapy: Focus on human studies
Anti-Cancer Agents in Medicinal Chemistry Cancer Therapeutics: Emerging Targets and Trends
Current Cancer Therapy Reviews The Quest for Surrogate Markers of Angiogenesis: A Paradigm for Translational Research in Tumor Angiogenesis and Anti- Angiogenesis Trials
Current Molecular Medicine